Demonstrated strength of KERENDIA payer coverage6
Resources to help support patient access to KERENDIA:
Learn more about navigating the Prior Authorization process for KERENDIA:
Prior Authorization Guide
Best practices on preparing and submitting a PA, requesting a medical exception, and navigating the appeals process for KERENDIA.
Prior Authorization Checklist
A reference checklist for HCPs and office staff that highlights key prior authorization criteria for KERENDIA.
Review these additional resources to help guide you through patient access to KERENDIA:
Sample Letter of Medical Necessity
An overview and templated example letter that can help support a patient’s health insurance claim by explaining the clinical rationale to prescribe KERENDIA.
Sample Letter of Medical Exception
An overview and templated example letter to request an exception on your patient’s behalf if their health plan does not cover KERENDIA on their formulary.
Sample Letter of Appeal
An overview and templated example letter to request an appeal when a patient’s insurance plan has denied their KERENDIA PA request.
Sample Tiering Exception Request Letter
An overview and templated example letter to request a tiering exception that may allow the patient to pay a lower co-pay or co-insurance for their KERENDIA prescription.
Help your patients fill their KERENDIA prescription with
BlinkRx provides a streamlined process that can help patients save time and money
For additional support or to submit prescriptions by phone or fax, contact BlinkRx:
Phone: 1 (866) 839-0766
Fax: 1 (866) 585-4631
Submit a Prior Authorization (PA) online using CoverMyMeds®† and access a full suite of resources available for your practice to help get your patients access to KERENDIA
- Prior Authorization and Appeals support
- Submit pharmacy-initiated Prior Authorization requests directly to your patient’s health plan
- Payer experts available by phone or through chat to address questions
- Weekly live demos of the CoverMyMeds® platform
*BlinkRx® is an independent party.
†CoverMyMeds® is an independent party.
INDICATION:
KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS:
- Concomitant use with strong CYP3A4 inhibitors
- Patients with adrenal insufficiency
WARNINGS AND PRECAUTIONS:
Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L
Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium
MOST COMMON ADVERSE REACTIONS:
- From the pooled data of 2 placebo-controlled studies, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3.9%), and hyponatremia (1.3% vs 0.7%)
DRUG INTERACTIONS:
- Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice
- Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIA dosage as appropriate
- Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers
USE IN SPECIFIC POPULATIONS:
- Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment
- Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B)
Please read the Prescribing Information for KERENDIA.
